A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
Public ClinicalTrials.gov record NCT07613294. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart disease. The main purpose of the study is to investigate how lepodisiran, compared to a placebo, affects the amount and type of plaque in the heart's vessels using an imaging technology known as Coronary Computed Tomography Angiography (CCTA) in adults who have high levels of Lp(a). Participation will last about 120 weeks.
Study identification
- NCT ID
- NCT07613294
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 252 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 45 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2026
- Primary completion
- Nov 30, 2029
- Completion
- Nov 30, 2029
- Last update posted
- Jul 27, 2026
2026 – 2029
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSD - Altman Clinical and Translational Research Institute (ACTRI) | La Jolla | California | 92037-7410 | Not yet recruiting |
| Valley Clinical Trials, Inc. | Northridge | California | 91325 | Recruiting |
| Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Torrance | California | 90502 | Not yet recruiting |
| Jellinger and Lerman, MD PA dba The Center for Diabetes and Endocrine Care | Fort Lauderdale | Florida | 33312 | Recruiting |
| Jacksonville Center for Clinical Research | Jacksonville | Florida | 32216 | Not yet recruiting |
| Merritt Island Medical Research, LLC | Merritt Island | Florida | 32952 | Recruiting |
| Inpatient Research Clinic | Miami Lakes | Florida | 33014 | Not yet recruiting |
| Clinical Site Partners, LLC dba Flourish Research | Winter Park | Florida | 32789 | Recruiting |
| CARE Institute - High Desert | Meridian | Idaho | 83642 | Not yet recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Not yet recruiting |
| Profound Research LLC | Farmington Hills | Michigan | 48334 | Recruiting |
| Vector Clinical Trials | Las Vegas | Nevada | 89128 | Recruiting |
| Heart and Vascular Research at WellSpan Health | York | Pennsylvania | 17403 | Not yet recruiting |
| Intermountain Medical Center | Murray | Utah | 84107 | Not yet recruiting |
| Virginia Heart - Leesburg | Leesburg | Virginia | 20176 | Not yet recruiting |
| Carilion Clinic | Roanoke | Virginia | 24014 | Recruiting |
| Eastside Research Associates | Redmond | Washington | 98052 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
Recently updated Atherosclerosis trials
Other public records listing Atherosclerosis. Sorted by last update posted; newest first. Not a recommendation.
- NCT07783802: A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event Not yet recruiting
- NCT07521007: A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis Not yet recruiting
- NCT05867381: Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History Recruiting
- NCT04496947: Pilot Study Evaluating the Impact of Stress Reduction on Atherosclerotic : Heart and Mind Study Recruiting
- NCT01399385: New Heart Imaging Techniques to Evaluate Possible Heart Disease Recruiting
- NCT07448038: A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07613294, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 27, 2026 · Synced Jul 31, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07613294 live on ClinicalTrials.gov.